SSI(SZ:002742)2024-04-29 18:16Financial Performance - The company's operating revenue for 2023 was ¥2,030,233,466.71, a decrease of 2.25% compared to ¥2,077,023,564.35 in 2022[21] - The net profit attributable to shareholders for 2023 was -¥452,046,680.05, representing a decline of 42.21% from -¥317,882,092.06 in 2022[21] - The basic earnings per share for 2023 was -¥1.05, down 41.89% from -¥0.74 in 2022[21] - The total assets at the end of 2023 were ¥3,841,158,437.01, a decrease of 4.94% from ¥4,040,800,589.29 at the end of 2022[21] - The net assets attributable to shareholders decreased by 56.96% to ¥345,287,512.91 in 2023 from ¥802,312,531.40 in 2022[21] - The company reported a net cash flow from operating activities of -¥51,594,597.21 in 2023, a decline of 205.05% compared to ¥49,115,363.42 in 2022[21] - The company's weighted average return on equity for 2023 was -78.78%, a decrease of 45.72% from -33.06% in 2022[21] - The revenue from the main business after deductions for 2023 was ¥2,004,387,733.05, compared to ¥2,054,891,639.60 in 2022[21] - The company reported a total revenue of CNY 2,129,233,466.71 for the year 2023, with a significant decline in net profit attributable to shareholders amounting to CNY -451,046,649.05, representing a decrease compared to previous years[25] - The first quarter revenue was CNY 497,422,619.12, while the fourth quarter revenue dropped to CNY 414,590,441.83, indicating a downward trend throughout the year[25] - The net cash flow from operating activities was CNY -86,577,129.95 in the fourth quarter, highlighting cash flow challenges faced by the company[25] - Non-recurring losses totaled CNY -25,106,054.84 for 2023, a significant increase from CNY -4,360,300.36 in 2022, indicating worsening financial conditions[27] Business Segments - The company has diversified into two main business segments: construction materials and pharmaceutical manufacturing, with a focus on concrete and pharmaceutical intermediates[35] - The construction materials segment primarily generates revenue from ready-mixed concrete, which is heavily influenced by local economic conditions and infrastructure investments[32] - The pharmaceutical manufacturing segment has established a full industry chain layout, contributing to the company's performance through the production of intermediates and active pharmaceutical ingredients[34] - The company is strategically positioned in the Chongqing region, benefiting from local economic growth and infrastructure development initiatives[32] - The company has faced challenges in the ready-mixed concrete and additives sector due to a rapid decline in market demand, impacting supply chain performance[35] - The company is responding to the "Belt and Road" initiative, with its construction materials segment in Ethiopia gaining market recognition and establishing a leading position[35] - The company has over 20 types of raw pharmaceutical products and more than 80 types of formulation products, including essential drugs like Paracetamol and Chlorpheniramine, which are commonly used in clinical settings[36] - The company has established a diversified business model, reducing operational risks associated with macroeconomic cycles, with the pharmaceutical sector being less correlated to economic fluctuations compared to the construction materials sector[37] - The company has a strong technical advantage with a dedicated R&D center for pharmaceuticals, focusing on antibiotic, digestive, respiratory, endocrine, and cardiovascular drugs, and has developed a pipeline for antiviral and antihypertensive medications[39] - The company is one of the largest producers of concrete additives in Southwest China, offering a wide range of products including superplasticizers and early-strength agents, and can provide customized solutions based on client needs[40] - The company has a strong brand presence, with its "San Sheng" trademark recognized as a national famous brand, enhancing its market position and customer relationships[41] - The company has formed a dual-driven business model integrating construction materials and pharmaceutical manufacturing, effectively mitigating the impact of raw material market fluctuations on operations[42] - The company is strategically located in Chongqing, benefiting from its status as a national central city and a key point in the "Belt and Road" initiative, which is expected to provide significant growth opportunities[42] - The company has a comprehensive product portfolio in pharmaceuticals, with over 20 types of raw materials and 80 types of formulations, ensuring a strong market position and customer base[41] - The company has established collaborative relationships with research institutions, enhancing its ability to meet diverse market demands through tailored solutions[38] - The company has a well-established team with decades of industry experience, enabling it to respond quickly to market dynamics and maintain stable growth[39] Revenue and Sales Performance - The construction materials segment generated ¥1,036,797,546.46, accounting for 51.07% of total revenue, down 9.00% from the previous year[47] - The pharmaceutical segment achieved revenue of ¥966,477,588.69, representing a 5.56% increase year-on-year, and accounted for 47.60% of total revenue[47] - Domestic revenue decreased by 16.10% to ¥1,745,760,779.90, while international revenue increased by 81.42% to ¥368,754,698.73[47] - The sales volume of ready-mixed concrete decreased by 2.58% to 233.43 million cubic meters[50] - The sales volume of pharmaceutical intermediates decreased by 52.61% to 3,187.09 tons compared to 6,725.83 tons in the previous year[51] - The sales volume of tablets increased by 50.22% to 300,398.66 million pieces, up from 199,972.19 million pieces in 2022[51] - The company's sales expenses rose by 25.68% to 60,110,923.34 yuan due to intensified market competition in the building materials sector[55] - The company's research and development expenses increased by 16.73% to 17,371,581.69 yuan, reflecting increased investment in the pharmaceutical sector[55] Cash Flow and Investment - The company reported a significant increase in financial costs due to tightened liquidity and rising financing costs, impacting overall profitability[44] - The investment activities generated a net cash outflow of 50,075,471.80 yuan, a significant decrease of 261.32% compared to the previous year[56] - The company's total investment during the reporting period was ¥77,259,140.32, representing a decrease of 5.60% compared to the previous year's investment of ¥81,839,091.91[61] - The total assets at the end of 2023 amounted to 3,839,000,000 yuan, with cash and cash equivalents decreasing by 32,381,614.57 yuan[59] Corporate Governance and Management - The company has maintained compliance with corporate governance regulations, ensuring transparency and protecting shareholder rights[77] - The company has established independent operations in business, personnel, assets, and finance, ensuring a clear separation from its controlling shareholders[78] - The company has conducted multiple shareholder meetings, with participation rates of 33.95% and 30.95% in recent meetings[79] - The company reported a total shareholding of 189.2 million shares at the end of the reporting period, with no changes in the number of shares held by directors and supervisors[81] - On March 16, 2023, several directors and a supervisor resigned due to personal reasons, including Du Dongchao and Chen Bingyao[82] - The company appointed new directors and a financial director on April 10 and April 21, 2023, respectively, to fill the vacancies left by resignations[82] - The current chairman, Yan Huan, has been with the company since November 2016, indicating stability in leadership[83] - Zhang Zhijiang, the current general manager, has a background in production management and has been with the company since its early years[84] - The company has maintained a consistent board structure with a mix of experienced professionals in key positions[83] - The financial director, Huang Zhongqiang, was appointed on April 21, 2023, reflecting the company's commitment to strong financial oversight[82] - The company has not reported any significant changes in its operational strategy following the management transitions[82] - The board of directors includes a diverse range of expertise, enhancing the company's governance and strategic direction[83] - The company continues to focus on maintaining its market position amidst leadership changes, ensuring continuity in its operations[82] Employee and Compensation - The total number of employees at the end of the reporting period is 2,039, with 1,240 in production, 109 in sales, 264 in technology, 64 in finance, and 362 in administration[97] - The company has 133 retired employees for whom it bears costs[97] - The company has established a performance-oriented compensation system, including base salary, performance bonuses, and excess incentive bonuses to motivate employees[98] - The total pre-tax remuneration for directors, supervisors, and senior management in 2023 amounted to CNY 491.25 million[89] - The highest remuneration was received by the General Manager, Zhang Zhiqiang, totaling CNY 89.72 million[89] - The company’s Vice General Manager, Xie Yun, received a remuneration of CNY 93.28 million in 2023[89] - The total remuneration for the Finance Director, Huang Zhongqiang, was CNY 46.77 million[89] - The company’s independent directors received a total of CNY 27.13 million in remuneration[89] - The company’s total remuneration for directors and supervisors reflects adherence to industry standards and performance evaluations[89] - The company’s management structure includes a diverse team with extensive experience in the pharmaceutical and financial sectors[89] - The company is committed to transparency in its remuneration policies, which are reviewed by the board and shareholders[89] Environmental Compliance - The company has implemented a comprehensive environmental remediation initiative to ensure sustainable operations[45] - The company has complied with various environmental protection laws and standards, ensuring adherence to national and industry regulations[113] - 重庆三圣实业股份有限公司的排污许可证有效期为2020年12月20日至2025年12月19日[114] - 重庆三圣实业股份有限公司减水剂分厂的排污许可证有效期为2023年7月20日至2028年7月19日[114] - 重庆三圣实业股份有限公司膨胀剂分厂的排污许可证有效期为2023年5月12日至2028年5月11日[114] - 四川武胜春瑞医药化工有限公司的排污许可证有效期为2023年7月20日至2028年7月19日[114] - 山东寿光增瑞化工有限公司的排污许可证有效期为2023年9月19日至2028年9月18日[114] - 辽源市百康药业有限责任公司的排污许可证有效期为2023年9月18日至2028年9月17日[114] - 重庆三圣实业股份有限公司的二氧化硫排放量为348.3吨/年，符合排放标准[115] - 四川武胜春瑞医药化工有限公司的氮氧化物排放量为18.62吨/年，符合排放标准[115] - 重庆三圣实业股份有限公司的颗粒物排放浓度为≤30 mg/m³，符合排放标准[115] - 重庆三圣实业股份有限公司的恶臭气体浓度为14554，符合排放标准[115] - The company reported a total nitrogen discharge of 1.36 tons per year, with ammonia nitrogen levels at 0.877 tons per year, adhering to GB 21 904 standards[117] - The wastewater treatment facility achieved a total phosphorus discharge of 3 mg/L, complying with GB 21904 standards[117] - The company has implemented a comprehensive waste gas treatment system, including bag filters and electrostatic precipitators, to ensure emissions meet environmental standards[117] - The company emphasizes environmental protection, conducting regular maintenance on pollution control facilities to ensure compliance with discharge standards[117] - The company has established an automatic online monitoring system for wastewater and gas emissions, managed by qualified third-party operators[117] - The company reported a total of 9.743 tons of ammonia nitrogen discharge from its wastewater treatment plant, adhering to GB standards[117] - The company has a recycling facility for production wastewater, utilizing biochemical methods for treatment before discharge[117] - The company has a sulfuric acid co-production cement line, which includes desulfurization facilities and automatic monitoring systems[117] - The company ensures hazardous waste is handled by qualified third-party units, while municipal waste is managed by local government[117] Legal and Financial Obligations - The company has unresolved issues related to fund occupation and irregular guarantees, with a total outstanding loan principal and interest of 121.34 million birr (approximately 15.24 million RMB) as of December 31, 2023[109] - The company has faced legal actions regarding the repayment of loans, with a total claim of 6,148.50 million CNY from Henghui Microfinance Company[134] - The company reported an increase of 1,572 million CNY in funds occupied during the reporting period[134] - The company is currently in the process of correcting non-compliance issues as mandated by regulatory authorities[132] - The company has acknowledged the need for measures to address the financial obligations arising from the loan agreements[134] - The company is applying for reorganization and pre-reorganization due to its inability to repay due debts and lack of repayment capacity, but it has reorganization value[142] - The company has recognized impairment provisions totaling 3.48 million RMB for mining rights intangible assets and 2.72 million RMB for construction in progress[172] - The company has a pending arbitration case with Shanghai Yihong Company, with a total outstanding amount of CNY 45.91 million, including CNY 2.50 million in interest for 2023[182] - The company has reached a settlement with Shenzhen High-tech Investment Group, with an outstanding principal of CNY 442 million and total liabilities of CNY 182.94 million, including interest and legal fees[185] - The company is involved in arbitration regarding a 15.90 million yuan debt, with additional claims for interest and penalties totaling 0.75 million yuan[190] - The company faces operational debt litigation totaling approximately 125.28 million yuan, which is still pending trial or hearing[192] Debt and Guarantees - The company has a guarantee responsibility of 3,500 million with a maturity date of June 30, 2023[158] - The total external guarantee amount approved during the reporting period was CNY 269.5 million, with an actual occurrence of CNY 6.493 million[159] - The total approved external guarantee amount at the end of the reporting period was CNY 262.952 million, with a guarantee balance of CNY 226.967 million[159] - The company provided guarantees for subsidiaries, with a guarantee amount of CNY 10 million for Chongqing Shengzhi Building Materials Co., Ltd., and CNY 20 million for Liaoyuan Baikang Pharmaceutical Co., Ltd.[159] - The actual guarantee amount for Liaoyuan Baikang Pharmaceutical Co., Ltd. was CNY 1 million, with a guarantee period ending on February 7, 2023[159] - The company has a total guarantee amount of CNY 10 million for Chongqing Liwan Commodity Concrete Co., Ltd., with an actual occurrence of CNY 1.01512 million[159] - The company reported a guarantee amount of CNY 10 million for Chongqing Liwan Commodity Concrete Co., Ltd. with an actual occurrence of CNY 1 million[159] - The company has completed the performance of guarantees for various subsidiaries, ensuring compliance with obligations[159] - The company continues to monitor and manage its guarantee obligations to mitigate financial risks[159] - The reporting period reflects a strategic focus on maintaining financial stability through careful management of guarantees[159] Strategic Initiatives - The company plans to enhance its production and operational management model, integrating resources across business segments to improve overall profitability[71] - The company aims to reduce costs and increase efficiency by optimizing resource allocation and production processes, targeting a comprehensive management approach[71] - The company will focus on expanding its international presence, particularly in Africa and surrounding countries, to promote its international trade business[71] - The company recognizes the risk of macroeconomic fluctuations affecting its operations, particularly in the construction materials sector, which is experiencing declining demand[72] - Raw material costs account for over 70% of the total costs for the company's main products, making it vulnerable to price fluctuations[72] - The company will leverage its competitive advantages in resources, technology, and management to navigate intense market competition in the concrete and additives sectors[72] - The company is committed to developing a green and environmentally friendly production model while enhancing its supply chain capabilities[70] - The company aims to strengthen its core business in building materials while developing its pharmaceutical manufacturing segment for diversified growth[70] - The company is facing significant funding pressure, with tight liquidity and is implementing measures to improve accounts receivable management and inventory turnover[20] - The company is expanding its international presence by establishing operations in Ethiopia for pharmaceutical and new building materials projects, aiming to penetrate the African market[20] - The company plans to enhance its supply chain capabilities and optimize payment methods to reduce interest-bearing liabilities and financing costs[20] - The company is actively seeking strategic investors to support its operations and strategic planning, providing necessary financial backing[20] Audit and Compliance - The company has reported a non-standard audit opinion from Tianjian Accounting Firm, which highlights objective and real concerns regarding financial statements[137] - The company has implemented measures to enhance supervision of management and board actions to improve operational sustainability[138] - The current auditor, Tianjian Accounting Firm, has been engaged for 12 years, with an audit fee of 2.1 million yuan[142] - There were no changes in accounting policies, estimates, or significant accounting errors compared to the previous year's financial report[140] - The company reported no major litigation or arbitration matters during the reporting period[143] - The company has not engaged in any related party transactions during the reporting period[145] - There were no changes in the scope of consolidated financial statements compared to the previous year[141] - The company faced administrative penalties for fund occupation and disclosure violations, with corrective measures ordered[144] - The company has not conducted any asset or equity acquisitions